A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2016
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 11 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Dec 2013 Planned End Date changed from 1 Mar 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.